Overview: Medullary Thyroid Carcinoma Mutation TestIntroduction: The Medullary Thyroid Carcinoma Mutation Test detects mutations to diagnose medullary thyroid cancer, causing neck swelling or pain. Following 2023 ATA guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected medullary thyroid cancer.
Other Names: MTC Mutation Assay, RET Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MTC mutation testing began in the 1990s with RET gene research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects mutations to diagnose medullary thyroid cancer, guides treatment, and evaluates patients with neck swelling or pain.
Test Parameters: 1. MTC Mutations
Pretest Condition: No fasting required. Collect whole blood, tissue, or saliva. Report history of neck swelling, pain, or thyroid cancer symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Tissue (FFPE, 0.5-2 cma³), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neck swelling, pain, weight loss, or family history of thyroid cancer. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, thyroid cancer implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect MTC mutations (e.g., RET gene) in specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for medullary thyroid cancer diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive MTC mutations confirm medullary thyroid cancer, guiding surgery or targeted therapy (e.g., vandetanib). Negative results may require further testing.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Calcitonin levels, thyroid ultrasound, or fine-needle aspiration to confirm medullary thyroid cancer diagnosis.
Test Limitations: Not all MTC mutations are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: ATA Thyroid Cancer Guidelines, 2023; Journal of Clinical Oncology, Wells SA, 2022.
